What are your top takeaways in Medical Oncology from SABCS 2025?  

lidERA trial. This is the first phase III trial showing an advantage for an oral SERD giredestrant over standard endocrine adjuvant therapy in early breast cancer. Treatment with giredestrant led to a 30% reduction in the risk of invasive disease recurrence over standard endocrine therapy at the fir...

I think that the lidERA study is probably the most exciting advance from the meeting. Having a new antiestrogen medication for early stage HR positive breast cancer, which is more effective than our current standards, will ultimately cure more patients, who make up the majority of early-stage breast...

My top takes are the results of the lidERA and Her2climb-05 trials.